The agreement extends the reach of Biocept's Target Selector testing to a large new region and brings its total reach to 17 countries outside the US.
The coverage decision limits the test mainly to patients with advanced lung cancers who haven't been genomically profiled and who can't receive tissue testing.
The company is confident about bringing the test to market despite potential future competition and views it as an easy fit for its existing sales channels.
The deal gives Biodesix an additional test in the lung cancer space, Indi's XL2, which helps to classify lung nodules identified by imaging scans as benign or malignant.
Under the new collaboration, Predicine will use its GeneRADAR technology to aid Kintor in the development and advancement of novel drugs.
Results support the ability of the test to not only identify hormonal therapy non-responders, but to predict their improved survival on chemotherapy.
The financing will support business expansion, continued technology development, and expenses related to a planned listing at the end of the year.
Bio-Techne will pay $250 million in cash, as well as up to an additional $325 million contingent on the achievement of certain milestones.
Proceeds will be used to support studies for regulatory submissions to the FDA for the company's metastatic breast cancer test, among other things.
The Belgian cancer center plans to evaluate Natera's ctDNA assay for evaluating response and detecting minimal residual disease in breast cancer patients.
In a commentary at eLife, Brandeis University's Eve Marder calls on researchers to value and pursue truth.
Researchers have developed a way to quickly edit white blood cells, according to the New York Times.
In Science this week: rice gene enables plants to grow quickly in times of flooding, and more.
Education-linked genetic variants could also predict a small portion of a person's social mobility, Newsweek reports.